Tazarotene - Valeant Pharmaceuticals

Drug Profile

Tazarotene - Valeant Pharmaceuticals

Alternative Names: IDP-123

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antiacnes; Antipsoriatics; Keratolytics; Nicotinic-acids; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 02 Jun 2017 Valeant Pharmaceuticals plans a phase III trial for Acne vulgaris (In adolescents, In adults, In children, In the elderly) (NCT03168334)
  • 24 May 2017 Valeant Pharmaceuticals plans a phase III trial for Acne Vulgaris (In children, In adolescents, In adults, In the elderly) (NCT03168321)
  • 16 Mar 2017 Valeant Pharmaceuticals plans a phase III trial for Psoriasis in 2017 (Valeant Pharmaceuticals pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top